SPX Technologies Inc reports a robust first quarter with significant revenue growth and upward revisions in annual forecasts.
Despite a net loss, Lexicon Pharmaceuticals Inc (LXRX) shows promising advancements in drug development and strategic financial maneuvers.
Despite a rise in net loss and a drop in revenue, Zymeworks Inc (ZYME) remains optimistic with strong cash reserves and strategic advancements in global clinical trials.